Inventor
ECONOMIDES ARIS N
US49 patents
⚠️ This page may combine multiple inventors who share the name “ECONOMIDES ARIS N”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
44 patentsUS6586251B2Jul 1, 2003
Methods of modifying eukaryotic cells
REGENERON PHARMA505 citations99
US7205148B2Apr 17, 2007
Genome mutation by intron insertion into an embryonic stem cell genome
REGENERON PHARMA93 citations98
US5470952ANov 28, 1995
CNTF and IL-6 antagonists
REGENERON PHARMA47 citations96
US9708635B2Jul 18, 2017
Methods of making a nucleic acid encoding a human variable region
REGENERON PHARMA9 citations93
US9388446B2Jul 12, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA6 citations93
US9371553B2Jun 21, 2016
Genetically modified mice that produce hybrid antibodies
REGENERON PHARMA6 citations93
US9353394B2May 31, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA6 citations93
US8846402B2Sep 30, 2014
Method for genetically modifying isolated non-human mammalian cell by homologous recombination
REGENERON PHARMA17 citations93
US7473557B2Jan 6, 2009
Method for targeting transcriptionally active loci
REGENERON PHARMA33 citations92
US9510569B2Dec 6, 2016
Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
REGENERON PHARMA12 citations91
US6610510B1Aug 26, 2003
Morphogenic proteins
REGENERON PHARMA20 citations91
US10640800B2May 5, 2020
Mice that produce hybrid antibodies
REGENERON PHARMA4 citations84
US10526630B2Jan 7, 2020
Genetically modified mice that produce hybrid antibodies
REGENERON PHARMA3 citations84
US10378037B2Aug 13, 2019
Methods of making a nucleic acid encoding a human variable region
REGENERON PHARMA3 citations84
US10378040B2Aug 13, 2019
Mice that produce hybrid antibodies
REGENERON PHARMA4 citations84
US10378038B2Aug 13, 2019
Mice that produce hybrid antibodies
REGENERON PHARMA3 citations84
US10378039B2Aug 13, 2019
Mouse embryonic stem cells comprising a hybrid heavy chain immunoglobulin locus
REGENERON PHARMA3 citations84
US10227625B2Mar 12, 2019
Methods of modifying eukaryotic cells
REGENERON PHARMA3 citations84
US9528136B2Dec 27, 2016
Methods of modifying eukaryotic cells
REGENERON PHARMA5 citations84
US9382567B2Jul 5, 2016
Methods of producing hybrid antibodies
REGENERON PHARMA3 citations84
US11578135B2Feb 14, 2023
Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
REGENERON PHARMA8 citations82
US9999207B2Jun 19, 2018
Nucleic acid construct for making a genetically modified rodent with an inducible ACVR1 mutation that causes ectopic bone formation
REGENERON PHARMA6 citations82
US10377817B2Aug 13, 2019
Human antibodies to GREM1
REGENERON PHARMA7 citations81
US10584364B2Mar 10, 2020
Mice that produce hybrid antibodies
REGENERON PHARMA1 citations73
US10344299B2Jul 9, 2019
Compositions and methods for modifying cells
REGENERON PHARMA3 citations73
US10531648B2Jan 14, 2020
Conditional rodent Acvr1 mutant gene
REGENERON PHARMA1 citations71
US10470444B2Nov 12, 2019
Method for making a genetically modified mouse with an inducible ACVR1 mutation that causes ectopic bone formation
REGENERON PHARMA1 citations71
US10448621B2Oct 22, 2019
Rodent embryonic stem cell with conditional ACVR1 mutant alleles
REGENERON PHARMA1 citations71
US11419319B2Aug 23, 2022
Genetically modified rodent with an inducible ACVR1 mutation in exon 7 that causes ectopic bone formation
REGENERON PHARMA2 citations69
US11407822B2Aug 9, 2022
Treatment of fibrodysplasia ossificans progressiva
REGENERON PHARMA2 citations69
US10392633B2Aug 27, 2019
Multifunctional alleles
REGENERON PHARMA2 citations68
US7285532B2Oct 23, 2007
Therapeutic method for treating bone formation diseases
REGENERON PHARMA2 citations63
US10988776B2Apr 27, 2021
Methods of modifying genes in eukaryotic cells
REGENERON PHARMA0 citations62
US11730150B2Aug 22, 2023
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA0 citations61
USRE49121EJul 5, 2022
Genetically modified mouse with an inducible ACVR1 gene with a mutant R206H exon 5 that has ectopic bone formation
REGENERON PHARMA0 citations61
US10548302B2Feb 4, 2020
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA1 citations61
US11634480B2Apr 25, 2023
Human antibodies to GREM1
REGENERON PHARMA0 citations60
US12473574B2Nov 18, 2025
Methods for modifying a genome
REGENERON PHARMA0 citations58
US12089576B2Sep 17, 2024
Nucleic acids comprising a modified rodent activin a receptor type 1 (Acvr1) gene
REGENERON PHARMA0 citations58
US11319557B2May 3, 2022
Multifunctional alleles
REGENERON PHARMA1 citations58
US6846908B2Jan 25, 2005
DCR-5 bone affecting ligand
REGENERON PHARMA0 citations52
US6660499B1Dec 9, 2003
DCR5, a BMP-binding protein, and applications thereof
REGENERON PHARMA0 citations52
US7241739B2Jul 10, 2007
Morphogenic protein
REGENERON PHARMA0 citations51
US11945872B2Apr 2, 2024
Anti-ACVR1 antibodies and uses thereof
REGENERON PHARMA0 citations48
MURPHY ANDREW J
2 patentsECONOMIDES ARIS N
2 patentsUS8759105B2Jun 24, 2014
Method for genetically modifying mouse embryonic stem cell by homologous recombination
ECONOMIDES ARIS N40 citations96
US9677129B2Jun 13, 2017
Method for detecting the replacement of an endogenous allele with a modified allele by homologous recombination in a mouse ES cell
ECONOMIDES ARIS N3 citations72